Cidara Therapeutics Announces Two Presentations On Innovative Drug-Fc Conjugate, CD388, At The 2024 OPTIONS XII For The Control Of Influenza Conference

BenzingaSep 25 08:05 ET

Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza

GlobeNewswireSep 23 08:00 ET

Express News | Cidara Therapeutics Strengthens Its Scientific Advisory Board With Infectious Disease Experts

ReutersSep 19 08:00 ET

H.C. Wainwright Maintains Cidara Therapeutics(CDTX.US) With Buy Rating, Maintains Target Price $24

Moomoo NewsSep 16 07:31 ET · Ratings

Express News | HC Wainwright & Co. Reiterates Buy on Cidara Therapeutics, Maintains $24 Price Target

BenzingaSep 16 06:35 ET

Cidara Therapeutics to Cut 30% Workforce; Shares Down After-Hours

MT NewswiresSep 12 16:51 ET